NY Symposium Tackles Emerging Agents, Pressing Questions in Lung Cancer

Author(s):

Leaders in thoracic medical oncology from major cancer centers will come together Saturday to discuss advances in the field of lung cancer treatment during the 8th Annual New York Lung Cancer Symposium® in New York City.

Mark G. Kris, MD

Mark G. Kris, MD, one of the symposium’s program directors, said the conference will cover next-generation approaches and drugs for treating patients with advanced non-small cell lung cancer (NSCLC), including acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and new treatment options for patients with tumors that test positive for the ALK gene translocation. Revised strategies for treating small cell lung cancers, an update on squamous cell lung cancers, and the potential of immune therapy approaches also will be discussed.

Román Pérez-Soler, MD

“It’s a great opportunity to meet the local and international experts to learn about controversies today and to see what treatments are going to be available in your pharmacy within the next year or so,” said Kris, who is the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan-Kettering Cancer Center in New York City.

Román Pérez-Soler, MD, who also is a program director, said the meeting helps fill a need for oncology specialists to keep abreast of rapid advancements in the field. Pérez-Soler is chairman and chief of the Department of Medical Oncology at Montefiore Medical Center and an associate director of Clinical Research at Albert Einstein Cancer Center in Bronx, New York.

“The amount of data being generated on a monthly basis is quite amazing,” said Pérez-Soler. “There is a need to update people almost constantly. It’s a very useful program for people who want to catch up on what’s going on in lung cancer treatment.”

The symposium will feature these presentations:

Overcoming Resistance to EGFR TKIs
ALK Inhibitors: State of the Art
Molecular Targeted Agents for Stage III NSCLC
New Horizons for Small Cell Lung Cancers
New Treatments for Squamous Cell Lung Cancer
Current Approaches to Supportive Care
Adjuvant Therapy
How I Approach Maintenance Therapy
PD-1/PD-L1 Inhibition: What Does the Future Hold?

In addition, there will be debates on whether bevacizumab-based therapy should be the front-line standard of care for stage IV nonsquamous NSCLC, and whether there is an optimal tyrosine kinase inhibitor in EGFR-mutant cancers. There also will be a discussion of challenging cases that confront clinicians.

Faculty members scheduled to make presentations include Alice T. Shaw, MD, of Massachusetts General Hospital and Harvard Medical School; Bryan J. Schneider, MD, of New York Presbyterian-Weill Cornell Medical Center; and Charles M. Rudin, MD, PhD, and Gregory J. Riely, MD, PhD, of Memorial Sloan-Kettering Cancer Center.

For further information, visit www.gotoper.com.

<<<

View coverage from the New York Lung Cancer Symposium